Treating menopausal symptoms with a tissue-selective estrogen complex

Gender Medicine

Volumn 8, Issue 2, 2011, Pages 57-68

  Levine, Jeffrey P ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

estrogens; menopause; selective estrogen receptor modulator; tissue selective estrogen complex

Indexed keywords

BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CLONIDINE; CONJUGATED ESTROGEN; DENOSUMAB; ESTROGEN; GABAPENTIN; GESTAGEN; ISOFLAVONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

AMENORRHEA; ARTICLE; BLOATING; BONE DENSITY; BREAST DISCOMFORT; BREAST DISEASE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CORONARY ARTERY DISEASE; DEPRESSION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; ESTROGEN ACTIVITY; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; LUMBAR SPINE; MASTALGIA; MENOPAUSAL SYNDROME; MUSCULOSKELETAL PAIN; OSTEOLYSIS; OSTEOPENIA; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VAGINA ATROPHY; VENOUS THROMBOEMBOLISM;

ATROPHY; BODY MASS INDEX; CLIMACTERIC; ENDOMETRIAL HYPERPLASIA; ESTROGENS, CONJUGATED (USP); FEMALE; HOT FLASHES; HUMANS; INDOLES; MENOPAUSE; POSTMENOPAUSE; QUALITY OF LIFE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; VAGINA; VASOMOTOR SYSTEM; VULVA; WOMEN'S HEALTH;

EID: 79955593156     PISSN: 15508579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genm.2011.03.008     Document Type: Article

References (59)

1. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci. 1990;592:52-86. (Pubitemid 20273207)
2. Feldman BM, Voda A, Gronseth E. The prevalence of hot flash and associated variables among perimenopausal women. Res Nurs Health. 1985;8:261-268.
3. Rödström K, Bengtsson C, Lissner L, et al. A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. Menopause. 2002;9:156-161. (Pubitemid 34492323)
4. Haines CJ, Xing SM, Park KH, et al. Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: The Pan-Asia menopause (PAM) study. Maturitas. 2005;52:264-276. (Pubitemid 41562199)
5. Erlik Y, Tataryn IV, Meldrum DR, et al. Association of waking episodes with menopausal hot flushes. JAMA. 1981;245:1741-1744. (Pubitemid 11096223)
6. Ohayon MM. Severe hot flashes are associated with chronic insomnia. Arch Intern Med. 2006;166:1262-1268. (Pubitemid 43967577)
7. Dennerstein L, Dudley EC, Hopper JL, et al. A prospective population-based study of menopausal symptoms. Obstet Gynecol. 2000;96:351-358.
8. Versi E, Harvey MA, Cardozo L, et al. Urogenital prolapse and atrophy at menopause: a prevalence study. Int Urogynecol J Pelvic Floor Dysfunct. 2001;12:107-110. (Pubitemid 32451986)
9. Bjarnason NH, Alexandersen P, Christiansen C. Number of years since menopause: spontaneous bone loss is dependent but response to hormone replacement therapy is independent. Bone. 2002;30:637-642. (Pubitemid 34270504)
10. Nilas L, Christiansen C. The pathophysiology of peri-and postmenopausal bone loss. Br J Obstet Gynaecol. 1989;96:580-587. (Pubitemid 19146815)
11. Melton LJ 3rd, Chrischilles EA, Cooper C, et al. Perspective. How many women have osteoporosis? J Bone Miner Res. 1992;7:1005-1010.
12. Melton LJ 3rd, Khosla S, Atkinson EJ, et al. Relationship of bone turnover to bone density and fractures. J Bone Miner Res. 1997;12:1083-1091. (Pubitemid 27264222)
13. van der KM, de Laet CE, McCloskey EV, et al. Risk factors for incident vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res. 2004;19:1172-1180. (Pubitemid 41110570)
14. Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol. 2009;27:2831-2837.
15. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med. 2000;132:788-793. (Pubitemid 30317793)
16. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006;295:2057-2071. (Pubitemid 44794007)
17. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause. 2004;11:11-33.
18. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17:25-54.
19. Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women's Health Initiative randomized trial. J Bone Miner Res. 2006;21:817-828. (Pubitemid 43787988)
20. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003;290:1729-1738. (Pubitemid 37430623)
21. Utian WH, Archer DF, Bachmann GH, et al. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause. 2008;15:584-602.
22. Pluchino N, Cubeddu A, Giannini A, et al. Progestogens and brain: an update. Maturitas. 2009;62:349-355.
23. Bitzer J. Progesterone, progestogens and psychosomatic health of the climacteric woman. Maturitas. 2009;62:330-333.
24. Goletiani NV, Keith DR, Gorsky SJ. Progesterone: review of safety for clinical studies. Exp Clin Psychopharmacol. 2007;15:427-444. (Pubitemid 350102230)
25. th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2005.
26. Hoffmann M, Hammar M, Kjellgren KI, et al. Changes in women's attitudes towards and use of hormone therapy after HERS and WHI. Maturitas. 2005;52:11-17. (Pubitemid 41242737)
27. Rolnick SJ, Kopher RA, DeFor TA, Kelley ME. Hormone use and patient concerns after the findings of the Women's Health Initiative. Menopause. 2005;12:399-404. (Pubitemid 41098652)
28. Helenius IM, Korenstein D, Halm EA. Changing use of hormone therapy among minority women since the Women's Health Initiative. Menopause. 2007;14:216-222. (Pubitemid 46673472)
29. Ness J, Aronow WS, Beck G. Menopausal symptoms after cessation of hormone replacement therapy. Maturitas. 2006;53:356-361. (Pubitemid 43163072)
30. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 2007;14:355-369.
31. McClung MR. Bisphosphonates. Endocrinol Metab Clin North Am. 2003;32:253-271. (Pubitemid 36378644)
32. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344-1352. (Pubitemid 29483192)
33. Imaz I, Zegarra P, Gonzalez-Enriquez J, et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2010;21:1943-1951.
34. Rabenda V, Hiligsmann M, Reginster JY. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother. 2009;10:2303-2315.
35. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-645. (Pubitemid 29384151)
36. Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol. 2004;104:837-844. (Pubitemid 40458815)
37. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006;295:1647-1657.
38. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol. 2000;152:950-964.
39. Komm BS. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod Sci. 2008;15:984-992.
40. Evista® [prescribing information]. Indianapolis, Ind: Eli Lilly & Company. 2007.
41. Pickar JH, Yeh I-T, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril. 2009;92:1018-1024.
42. Lindsay R, Gallagher JC, Kagan R, et al. Efficacy of tissue-selective estrogen complex of bazedoxifene/ conjugated estrogens (BZA/CE) for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril. 2009;92:1045-1052.
43. Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril. 2009;92:1025-1038.
44. Archer DF, Lewis V, Carr BR, et al. Bazedoxifene/ conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril. 2009;92:1039-1044.
45. Pinkerton JV, Utian WH, Constantine GD, et al. Relief of vasomotor symptoms with the tissue selective estrogen complex containing bazedoxifene/ conjugated estrogens: a randomized, controlled trial. Menopause. 2009;16:1116-1124.
46. Kagan R, Williams RS, Pan K, et al. A randomized, placebo-and active-controlled trial of bazedoxifene/ conjugated estrogens (BZA/CE) for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause. 2010;17:281-289.
47. Utian W, Yu H, Bobula J, et al. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas. 2009;63:329-335.
48. Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/ conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/ vaginal atrophy. Climacteric. 2010;13:132-140.
49. Wattanakumtornkul S, Chichareon S, Geater A, et al. Compliance with hormone replacement therapy at Songklanagarind Hospital. J Obstet Gynaecol Res. 2003;29:380-387. (Pubitemid 38180674)
50. Manonai J, Theppisai U, Suchartwatnachai C, et al. Compliance with hormone replacement therapy in Thai women. Maturitas. 2003;44:201-205. (Pubitemid 36315816)
51. Pickar JH, Yeh I, Wheeler JE, et al. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;76:25-31. (Pubitemid 32600955)
52. Pickar JH, Yeh IT, Wheeler JE, et al. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril. 2003;80:1234-1240. (Pubitemid 37377757)
53. Stovall DW, Utian W, Gass ML, et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause. 2007;14:510-517.
54. Davis SR, O'Neill SM, Eden J, et al. Transition from estrogen therapy to raloxifene in postmenopausal women: Effects on treatment satisfaction and the endometrium-a pilot study. Menopause. 2004;11:167-175. (Pubitemid 40353234)
55. Carranza-Lira S, Gooch AL, Saldivar N, Osterwalder MS. Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses. Int J Fertil Womens Med. 2007;52:93-96.
56. Archer DF, Dorin M, Lewis V, et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril. 2001;75:1080-1087. (Pubitemid 32522601)
57. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol. 1994;83:686-692. (Pubitemid 24153460)
58. Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol. 2005;105:1063-1073. (Pubitemid 40571027)
59. Crandall CJ, Karlamangla A, Huang MH, et al. Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy. Arch Intern Med. 2006;166:1578-1584. (Pubitemid 44232365)